What are the indications, dosing regimens (including renal adjustments), therapeutic monitoring, and contraindications for amikacin?

Amikacin: Clinical Overview

Amikacin is a second-line injectable aminoglycoside primarily used for drug-resistant tuberculosis and serious gram-negative infections, dosed at 15 mg/kg/day (maximum 1 g/day) IM or IV in adults with normal renal function, with mandatory therapeutic drug monitoring to prevent nephrotoxicity and ototoxicity. 1, 2

Primary Indications

Amikacin serves specific clinical roles:

• Drug-resistant tuberculosis where organisms demonstrate or are presumed susceptible 1
• Serious gram-negative infections including hospital-acquired pneumonia in high-risk patients 3
• Carbapenem-resistant Enterobacterales (CRE) infections as part of combination therapy 4
• Non-tuberculous mycobacterial pulmonary disease (NTM-PD) 5

The drug is particularly valuable because most streptomycin-resistant strains remain susceptible to amikacin, and serum concentration measurements are readily available compared to other injectable agents 1.

Standard Dosing Regimens

Adults with Normal Renal Function

For tuberculosis treatment:

• 15 mg/kg/day (maximum 1 g/day) IM or IV as single daily dose, 5-7 days/week initially 1
• Reduce to 2-3 times weekly after first 2-4 months or after culture conversion 1
• Patients >59 years: reduce to 10 mg/kg/day (750 mg maximum) 1

For other serious infections (FDA-approved):

• 15 mg/kg/day divided into 2-3 equal doses 2
  • Either 7.5 mg/kg every 12 hours
  • Or 5 mg/kg every 8 hours
• Maximum daily dose: 1.5 g/day regardless of weight 2
• Uncomplicated UTI: 250 mg twice daily may suffice 2

For NTM-PD:

• 15 mg/kg once daily or 7.5 mg/kg twice daily 5
• 15-25 mg/kg three times weekly for intermittent dosing 5

Pediatric Dosing

• Children and older infants: 15-30 mg/kg/day (maximum 1 g/day) as single daily dose 1, 2
• Newborns: loading dose of 10 mg/kg, then 7.5 mg/kg every 12 hours 2

Obesity Adjustment

For markedly obese patients, calculate adjusted dose using: ideal body weight + 40% of excess weight 5

Renal Dose Adjustments

Critical principle: In renal impairment, reduce dosing frequency but maintain the milligram dose at 12-15 mg/kg to preserve concentration-dependent bactericidal effect. 1

Adjustment Strategies

Method 1: Normal dose at prolonged intervals

• Calculate interval (hours) = serum creatinine (mg/dL) × 9 2
• Example: If creatinine = 2 mg/dL, give 7.5 mg/kg every 18 hours

Method 2: Reduced dose at fixed intervals

• Give loading dose of 7.5 mg/kg initially 2
• Maintenance dose every 12 hours = (observed CrCl/normal CrCl) × loading dose 2
• Alternative: divide normal dose by serum creatinine value 2

For hemodialysis patients:

• Dose at 12-15 mg/kg, 2-3 times weekly 1
• Administer after dialysis to facilitate directly observed therapy and avoid premature drug removal 1

Neither method should be used during active dialysis. 2

Therapeutic Drug Monitoring

Serum concentration monitoring is mandatory to ensure efficacy and avoid toxicity. 1, 2

Target Concentrations

For daily dosing:

• Peak (30-90 min post-infusion): 25-35 mg/L 5
• Trough (pre-dose): <5 mg/L 5
• Avoid peaks >35 mcg/mL and troughs >10 mcg/mL 2

For three-times-weekly dosing:

• Peak: 65-80 mg/L 5
• Trough: <5 mg/L 5

Monitoring Schedule

• Peak level: within first week, repeat if poor response 5
• Trough levels: weekly for 4 weeks, then can reduce to fortnightly when stable 5
• Renal function: monthly assessments 1
• Auditory/vestibular symptoms: monthly questioning 1

Baseline and Follow-up Testing

Before initiating therapy:

• Audiogram
• Vestibular testing
• Romberg testing
• Serum creatinine 1

During therapy:

• Repeat audiogram and vestibular testing if symptoms of eighth nerve toxicity develop 1

Administration

IV infusion:

• Add 500 mg vial to 100-200 mL sterile diluent (0.9% NaCl or 5% dextrose) 2
• Adults: infuse over 30-60 minutes 2
• Pediatrics: infuse over 30-60 minutes 2
• Infants: infuse over 1-2 hours 2

Do not physically premix with other drugs; administer separately. 2

Major Contraindications

Absolute contraindication:

• Pregnancy - risk of fetal nephrotoxicity and congenital hearing loss 1

Relative contraindications/use with extreme caution:

• Pre-existing renal impairment (increased ototoxicity and nephrotoxicity risk) 1
• Pre-existing hearing loss or vestibular dysfunction
• Concurrent use of other nephrotoxic agents 4
• Neuromuscular disorders (risk of respiratory paralysis) 5

Adverse Effects and Risk Mitigation

Nephrotoxicity (Most Common)

Incidence: 8.7% overall; 3.4% in patients without risk factors 1

Amikacin is more nephrotoxic than streptomycin but comparable to kanamycin. 1

Risk factors:

• Elevated baseline creatinine
• Larger total cumulative doses
• Concurrent nephrotoxic agents (especially vancomycin) 1, 4
• Severe hepatic disease (predisposition to hepatorenal syndrome) 1

Mitigation:

• Avoid other nephrotoxic drugs when possible 4
• Maintain trough concentrations <5 mg/L 5
• Monitor renal function closely in high-risk patients 1

Ototoxicity

Incidence: 1.5-24% depending on study and definition 1

Characteristics:

• Primarily causes deafness (auditory > vestibular dysfunction) 1, 6
• Less vestibular dysfunction than streptomycin 1
• Irreversible vestibulocochlear nerve damage 5
• Higher risk with prolonged treatment, higher doses, older age 1, 5
• Increased risk with concurrent diuretics 1

Mitigation:

• Limit treatment duration to short-term whenever feasible 2
• Avoid concurrent diuretics when possible
• Regular audiometric monitoring

Other Adverse Effects

• Electrolyte disturbances: hypocalcemia, hypomagnesemia, hypokalaemia 5
• Neuromuscular blockade: respiratory paralysis (more common in neuromuscular disease, usually dose-related and self-limiting) 5

Treatment Duration and Re-evaluation

Standard duration: 7-10 days for most infections 2

For tuberculosis: Continue daily dosing for 2-4 months or until culture conversion, then reduce to 2-3 times weekly 1

If treatment beyond 10 days is considered:

• Re-evaluate necessity of amikacin 2
• If continued, monitor serum levels and renal, auditory, and vestibular functions closely 2

If no clinical response within 3-5 days:

• Stop therapy
• Recheck antibiotic susceptibility pattern
• Consider organism resistance or septic foci requiring surgical drainage 2

Special Populations

Hepatic Disease

No dose adjustment necessary 1

However, patients with severe hepatic disease require closer renal function monitoring due to hepatorenal syndrome risk 1

CNS Infections

Poor CNS penetration - only low concentrations reach CSF, even with meningitis 1

Consider alternative agents for primary CNS infections.

Critical Illness

Recent evidence suggests critically ill elderly patients may require higher initial doses (25-30 mg/kg) with TDM-guided adjustment, as volume of distribution is often increased 7, 8

Key Clinical Pitfalls

1. Do not reduce the milligram dose in renal impairment - only extend the interval to maintain concentration-dependent killing 1

2. Always give after dialysis, not before, to prevent premature drug removal 1

3. Do not use fixed dosing - always calculate based on actual body weight (adjusted for obesity) 2, 5

4. Do not skip TDM - serum concentration monitoring is not optional; it's essential for both efficacy and safety 1, 2

5. Avoid combining with vancomycin when possible - significantly increases nephrotoxicity risk 4

6. Do not continue empirically beyond 3-5 days without clinical response - reassess susceptibility and source control 2